NovoCure Limited Ordinary Shares
$16.69
-$0.03 (-0.18%)
$16.52Day Range$16.87
Key Statistics
Market Cap
$1.94B
Shares Outstanding
116.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 2, 2015
Round Lot
100
Locale
US
Trading Data
Day Open
$16.70
Day High
$16.87
Day Low
$16.52
Volume
1.15M
VWAP
$16.69
Prev Close
$16.72
Transactions
--
Acc. Volume
--
About NovoCure Limited Ordinary Shares
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSSIC 38411,605 employeesNO. 4 THE FORUM, ST. HELIER44 (0)15 3475 6700IPO Oct 2, 2015US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001645113
- Ticker Root
- NVCR
- SIC Code
- 3841
About NovoCure Limited Ordinary Shares (NVCR) Stock
NovoCure Limited Ordinary Shares (NVCR) closed the 2026-09-18 session at $16.69, down 0.18% versus the previous close (-0.03). The stock opened at $16.70 and traded between $16.52 and $16.87 during that session. Session trading volume was 1.2M shares. The volume-weighted average price (VWAP) is $16.69.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
NovoCure Limited Ordinary Shares has a market capitalization of $1.94 billion. The company operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry classification. NVCR is listed on the XNAS exchange. The company employs approximately 1,605 people. The recorded listing date is 2015-10-02.
On this page you can find market NVCR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector.